Loberg Michael D's Form 4 filing
IGM Biosciences, Inc. (IGMS) · filed Oct 3, 2022
- Accession no.
- 0001209191-22-051986
- Filed
- Oct 3, 2022
- Trade date
- Sep 29-30, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $114.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Loberg Michael DCIK 0001233414 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 29, 2022 | Common Stock | PPurchaseAcquired | +5,821 | $19.62F1 | +$114,208.02 | 35,305 | Indirect | |
| Sep 30, 2022 | Common Stock | AGrant or awardAcquired | +533 | $0.00 | $0 | 533 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was executed in multiple trades at prices ranging from $19.36 to $19.80. The price reported above reflects the weighted average purchase price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate purchase price.
Referenced by the price of 1 transaction in Table I.